SCHEMBL31364129

SCHEMBL31364129

NCC(=O)N1CCCC[C@H]1C(=O)O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACE P12821 6/20 0.56
DPP4 P27487 1/20 0.50
PREP P48147 1/20 0.50
FAP Q12884 1/20 0.50
DPP8 Q6V1X1 1/20 0.50
DPP9 Q86TI2 1/20 0.50
MVD P53602 2/20 0.47
REN P00797 2/20 0.45
LMNA P02545 2/20 0.45
HSD17B10 Q99714 2/20 0.45
CYP2C19 P33261 1/20 0.45
KDM4E B2RXH2 1/20 0.45
F2 P00734 1/20 0.45
LTA4H P09960 1/20 0.45
MAPT P10636 1/20 0.45
PEPD P12955 1/20 0.45
ALOX15 P16050 1/20 0.45
PTGS1 P23219 1/20 0.45
HTR2A P28223 1/20 0.45
PTGS2 P35354 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Glycyl Proline SCHEMBL155067 0.94 ACE (0.62) ACEDPP4PREPFAPDPP8
Glycyl Proline SCHEMBL155066 0.94 ACE (0.62) ACEDPP4PREPFAPDPP8
Glycyl Proline SCHEMBL30051559 0.94 ACE (0.62) ACEDPP4PREPFAPDPP8
Glycyl Proline SCHEMBL4168006 0.93 ACE (0.60) ACEDPP4PREPFAPDPP8
Glycyl Proline SCHEMBL4167998 0.93 ACE (0.60) ACEDPP4PREPFAPDPP8
Glycyl Proline SCHEMBL28116177 0.91 ACE (0.58) ACEDPP4PREPFAPDPP8
Glycyl Proline SCHEMBL28116179 0.91 ACE (0.58) ACEDPP4PREPFAPDPP8
SCHEMBL29777459 0.88 ACE (0.55) ACEDPP4PREPFAPDPP8
SCHEMBL10656884 0.88 ACE (0.55) ACEDPP4PREPFAPDPP8
Glycyl Proline SCHEMBL6660425 0.85 ACE (0.53) ACEDPP4PREPFAPDPP8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250171776-A1 NON-CANONICAL CELL-PENETRATING PEPTIDES FOR ANTISENSE OLIGOMER DELIVERY SAREPTA THERAPEUTICS, INC. (US) 2025-05-29 US claimed
US-20250171776-A1 NON-CANONICAL CELL-PENETRATING PEPTIDES FOR ANTISENSE OLIGOMER DELIVERY SAREPTA THERAPEUTICS, INC. (US) 2025-05-29 US disclosed
WO-2025030099-A1 NON-CANONICAL CELL-PENETRATING PEPTIDES FOR ANTISENSE OLIGOMER DELIVERY SAREPTA THERAPEUTICS, INC. (US) 2025-02-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250171776-A1 NON-CANONICAL CELL-PENETRATING PEPTIDES FOR ANTISENSE OLIGOMER DELIVERY MYOF, TNNC1, MTPN ACE 2907/4885DPP4 507/4885PREP 1418/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.